Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Aniracetam and PRL-8-53 — mechanism, side effects, legal status, and pricing.
Aniracetam is a non-peptide pyrrolidinone derivative and positive allosteric modulator of AMPA-type glutamate receptors. It is marketed as a prescription drug for cognitive disorders in some European countries (Italy, Greece) but has never been approved by the US FDA as either a drug or dietary supplement ingredient. The compound was reportedly withdrawn from the Japanese market following a failed confirmatory trial. Despite lacking US regulatory approval, aniracetam is openly sold online by nootropic-supplement retailers, often with significant label-accuracy problems.
PRL-8-53 is a non-peptide small-molecule aminoalkyl benzoic acid ester (methyl benzoate derivative), supplied as the hydrochloride salt. Originally characterized in 1974 animal studies as a spasmolytic and CNS-active agent, it has never been approved by any regulatory agency and is sold only as a research chemical. Exactly one published human trial exists—a 1978 double-blind study on verbal learning and retention—with no independent replication or modern safety data.
Aniracetam
PRL-8-53
Category
Legal Status
Mechanism
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Aniracetam
No pricing data yet.
Check Aniracetam prices →PRL-8-53
COA corpus from Disclosed Labs — independently tested batches only.
Aniracetam
2
COAs
99.5%
Avg purity
2
Labs
PRL-8-53
3
COAs
96.8%
Avg purity
2
Labs
The principal human efficacy evidence is one 6-month, double-blind, placebo-controlled multicenter trial in 109 elderly patients meeting probable-Alzheimer's criteria, which showed significant improvement in psychobehavioral parameters versus placebo with excellent reported tolerability, though no itemized adverse-event breakdown was available. No long-term (multi-year) human safety data were located, and no interventional trials of aniracetam are currently registered on ClinicalTrials.gov. In rodent models, aniracetam (50 mg/kg/day for 10 postnatal days) reversed prenatal-ethanol-induced avoidance-learning deficits in rat offspring and increased AMPA-receptor-mediated synaptic currents in hippocampal CA1 pyramidal cells. However, oral aniracetam (50 mg/kg, 5 days/week for 6 weeks) produced no cognitive or behavioral enhancement in healthy adult C57BL/6J mice across a comprehensive test battery.
Key references
Exactly one published human study was located: a 1978 double-blind trial (Hansl & Mead, <em>Psychopharmacology</em>, PMID 418433) using the serial anticipation method to test oral PRL-8-53 on verbal learning acquisition and retention, with follow-up on visual reaction time and motor control; the study reported statistically significant retention improvement (most P<0.01) and no significant reaction-time or motor effects, but sample size and exact dose are not stated in the available abstract. No further human trials were found, and no ClinicalTrials.gov entries exist. Preclinical work is limited to the 1974 Hansl paper (PMID 4824605) in dogs and rats, indexed for avoidance learning, conditioning, memory, and pharmacological interaction with apomorphine and methamphetamine, though full quantitative findings could not be verified because no abstract text is available.
Aniracetam and PRL-8-53 are both in the Cognitive category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Disclosed Labs